ALXP
ALTAO
Market cap12mUSD
Oct 28, Last price
0.01EUR
1D
0.00%
1Q
-1.92%
Jan 2017
-98.76%
IPO
-99.79%
Name
Hybrigenics SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in France, Aton operates as a bioscience enterprise, with its headquarters located in Strasbourg. Established in 1998, the company's extensive operations encompass pharmaceutical research and development, the provision of preclinical and clinical services, and the creation of monoclonal antibodies. Additionally, Aton manufactures laboratory equipment, designs and produces various medical devices—including specialized surgical instruments powered by Stemcis technology—and supplies human tissues.
Key people
Chairman of the Board · since 2015
Guillaume Floch
Chief Financial Officer · since 2008
Etienne Formstecher
Chief Executive Officer of Hybrigenics Services · since 2014
Remi Delansorne
Chief Executive Officer, Director · since 2007
Piet Serrure
Director - representing Rendex NV · since 2008
Albert Saporta
Independent Director · since 2012
Headquarters & legal address
850 BOULEVARD SEBASTIEN BRANT
ILLKIRCH-GRAFFENSTADEN 67400
FR
ILLKIRCH-GRAFFENSTADEN 67400
FR
Previous name
HYBRIGENICS SA
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |